Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
Intangible Assets
Ascendis Pharma A/S
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Intangible Assets
€3.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Intangible Assets
kr9.1B
|
CAGR 3-Years
657%
|
CAGR 5-Years
177%
|
CAGR 10-Years
78%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Intangible Assets
kr45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Intangible Assets
kr6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
51%
|
|
|
Saniona AB
STO:SANION
|
Intangible Assets
kr4.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Ascendis Pharma A/S
Glance View
Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.
See Also
What is Ascendis Pharma A/S's Intangible Assets?
Intangible Assets
3.7m
EUR
Based on the financial report for Dec 31, 2025, Ascendis Pharma A/S's Intangible Assets amounts to 3.7m EUR.
What is Ascendis Pharma A/S's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
11%
Over the last year, the Intangible Assets growth was -8%. The average annual Intangible Assets growth rates for Ascendis Pharma A/S have been -8% over the past three years , 11% over the past five years .
